52530-60-6 Usage
General Description
ANGIOTENSIN I/II (4-8), also known as Angiotensin IV, is a peptide that is derived from the cleavage of angiotensin II. It is a potent regulator of the renin-angiotensin system, which plays a critical role in regulating blood pressure and fluid balance. Angiotensin IV has been shown to have various physiological effects, including modulation of vascular tone, stimulation of aldosterone secretion, and enhancement of cognitive function. It also has potential therapeutic applications for conditions such as hypertension, Alzheimer's disease, and cognitive dysfunction. Additionally, research has demonstrated that Angiotensin IV may have neuroprotective effects and could be beneficial in the treatment of neurodegenerative diseases. Overall, Angiotensin I/II (4-8) is an important peptide with diverse biological activities and potential clinical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 52530-60-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,5,3 and 0 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 52530-60:
(7*5)+(6*2)+(5*5)+(4*3)+(3*0)+(2*6)+(1*0)=96
96 % 10 = 6
So 52530-60-6 is a valid CAS Registry Number.
InChI:InChI=1/C35H45N7O7/c1-3-21(2)30(41-31(44)26(36)16-23-11-13-25(43)14-12-23)33(46)39-27(18-24-19-37-20-38-24)34(47)42-15-7-10-29(42)32(45)40-28(35(48)49)17-22-8-5-4-6-9-22/h4-6,8-9,11-14,19-21,26-30,43H,3,7,10,15-18,36H2,1-2H3,(H,37,38)(H,39,46)(H,40,45)(H,41,44)(H,48,49)/t21-,26-,27-,28-,29-,30-/m0/s1
52530-60-6Relevant articles and documents
Novel synthesis of cyclic amide-linked analogues of angiotensins II and III
Matsoukas,Hondrelis,Agelis,Barlos,Gatos,Ganter,Moore,Moore
, p. 2958 - 2969 (2007/10/02)
Cyclic amide-linked angiotensin II (ANGII) analogues have been synthesized by novel strategies, in an attempt to test the ring clustering and the charge relay bioactive conformation recently suggested. These analogues were synthesized by connecting side chain amino and carboxyl groups at positions 1 and 8, 2 and 8, 3 and 8, and 3 and 5, N-terminal amino and C-terminal carboxyl groups at positions 1 and 8, 2 and 8, and 4 and 8, and side chain amino to C-terminal carboxyl group at positions 1 and 8. All these analogues were biologically inactive, except for cyclic [Sar1,Asp3,Lys5]ANGII (analogue 10) which had high contractile activity in the rat uterus assay (30% of ANGII) and [Lys1,Tyr(Me)4,Glu8]ANGII (analogue 7) which had weak antagonist activity (PA2 ? 6). Precyclic linear peptides synthesized using 2-chlorotrityl chloride resin and N(α)-Fmoc-amino acids with suitable side chain protection were obtained in high yield and purity and were readily cyclized with benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate as coupling reagent. Molecular modeling suggests that the ring structure of the potent analogue can be accommodated in the charge relay conformation proposed for ANGII.
